Anti-tumor necrosis factor agents may have cardioprotective effects in rheumatoid arthritis patients
Search results for: inhibitor
Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease
RA Treatment Options Expanded with New Infusible TNF Inhibitor
FDA approves second infusible anti–tumor necrosis factor treatment for patients with moderate to severe rheumatoid arthritis. (posted Aug. 16, 2013)
Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis
Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities
ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise
Toxicity and appropriate targeting are challenges for small molecule researchers
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
The Prospect of Rheumatoid Arthritis Prevention
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
Telehealth Triage Study Seeks to Close Gaps in Care
Reducing the time to diagnosis and initiation of appropriate treatment is paramount to intercept inflammatory damage in patients at the onset of rheumatic disease. But those targets can be delayed by provider shortages and other barriers to care. Since last June, Remission Medical, a virtual rheumatology clinic, has been partnering with Mayo Clinic to find…
3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
FDA Approves New Biosimilars to Denosumab with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 110
- Next Page »